Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

The Development of a Standardized Neighborhood Deprivation Index

Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain

Mazagatos, C., Delgado‐Sanz, C., Monge, S., Pozo, F., Oliva, J. A., Sandonis, V., Gandarillas, A., Rubio, C. Q., Ruiz‐Sopeña, C., García, V. G., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13026 · Cited by 12

A panel regression analysis for the COVID-19 epidemic in the United States

Guo, Y., Li, B., Duan, T., Yao, N., Wang, H., Yang, Y., Yan, S., Sun, M., Wang, L., Yao, Y., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273344 · Cited by 11

The benefits and costs of U.S. employer COVID‐19 vaccine mandates

Ferranna, M., Robinson, L. A., Cadarette, D., Eber, M. R., & Bloom, D. E. (2023) · Risk Analysis · doi:10.1111/risa.14090 · Cited by 11

Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19–Associated Encounters in Adults During Delta and Omicron Predominance

Bozio, C. H., Butterfield, K. A., Hagen, M. B., Grannis, S. J., Drawz, P. E., Hartmann, E., Ong, T. C., FIREMAN, B. H., Natarajan, K., Dascomb, K. K., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad040 · Cited by 11

A Novel Mathematical Model That Predicts the Protection Time of SARS-CoV-2 Antibodies

Xu, Z., Wei, D., Zhang, H., & Jacques Demongeot, A. (2023) · Viruses · doi:10.3390/v15020586 · Cited by 12

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis

Katoto, P. D., Tamuzi, J. L., Brand, A., Marangu, D., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2214495 · Cited by 13

Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial

Hejazi, N. S., Shen, X., Carpp, L. N., Benkeser, D. C., Follmann, D. A., Janes, H., Baden, L. R., Sahly, H. M. E., Deng, W., Zhou, H., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.012 · Cited by 11

Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity

Razonable, R. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397040 · Cited by 11

Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study

Ejima, K., Kim, K. S., Bento, A. I., Iwanami, S., Fujita, Y., Aihara, K., Shibuya, K., & Iwami, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07646-2 · Cited by 11

Young Age, Female Sex, and No Comorbidities Are Risk Factors for Adverse Reactions after the Third Dose of BNT162b2 COVID-19 Vaccine against SARS-CoV-2: A Prospective Cohort Study in Japan

Urakawa, R., Isomura, E. T., Matsunaga, K., & Kubota, K. (2022) · Vaccines · doi:10.3390/vaccines10081357 · Cited by 11

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study

Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · mBio · doi:10.1128/mbio.01212-23 · Cited by 11

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general populationPreprint

Wei, J., Matthews, P. C., Stoesser, N. E., Newton, J. N., Diamond, I. D., Studley, R., Taylor, N. P., Bell, J. I., Farrar, J., Kolenchery, J. B., et al. (2022) · medRxiv · doi:10.1101/2022.11.29.22282916 · Cited by 11

Addressing message fatigue for encouraging COVID-19 vaccination

Okuhara, T., Okada, H., & Kiuchi, T. (2023) · Journal of Communications In Healthcare · doi:10.1080/17538068.2023.2207246 · Cited by 10

COVID‐19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy

du Preez, H. N., Lin, J., Maguire, G. E. M., Aldous, C. M., & Kruger, H. G. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14296 · Cited by 12

Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population

Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11

SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Health Care Workers: A Prospective Cohort Study

Kim, N., Shin, S., Minn, D., Park, S., An, D., Park, J. H., Roh, E. Y., Yoon, J. H., & Park, H. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac035 · Cited by 10

VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern

O’Donnell, K. L., Gourdine, T., Fletcher, P., Shifflett, K., Furuyama, W., Clancy, C. S., & Marzi, A. (2022) · Vaccines · doi:10.3390/vaccines10030435 · Cited by 8

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Pattni, K., Hungerford, D., Adams, S., Buchan, I. E., Cheyne, C. P., García‐Fiñana, M., Hall, I., Hughes, D. M., Overton, C. E., Zhang, X. N., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07239-z · Cited by 11

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Haggenburg, S., Hofsink, Q., Rutten, C. E., Nijhof, I. S., Hazenberg, M. D., & Goorhuis, A. (2022) · Seminars in Hematology · doi:10.1053/j.seminhematol.2022.11.001 · Cited by 10

mRNA-Based COVID-19 Booster Vaccination is Highly Effective And Cost-Effective In Australia

Li, R., Liu, H., Fairley, C. K., Ong, J. J., Guo, Y., Lu, P., Zou, Z., Xie, L., Zhuang, G., Li, Y., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2023.01.075 · Cited by 10

Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021–July 2022

Plumb, I. D., Mohr, N. M., Hagen, M., Wiegand, R. E., Dumyati, G. K., Harland, K. K., Krishnadasan, A., James-Gist, J., Abedi, G. R., Fleming-Dutra, K. E., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad457 · Cited by 12

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis

Papadopoulos, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Evangelakou, Z., Malandrakis, P., Manola, M. S., Gianniou, D. D., Kastritis, E., Trougakos, I. P., Dimopoulos, M. A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020204 · Cited by 8

Efficacy of antibody response following the vaccination of SARS‐CoV‐2 infected and noninfected healthcare workers by two‐dose inactive vaccine against COVID‐19

Dündar, B., Karahangil, K., ELGORMUS, C. S., & Topsakal, H. N. H. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27649 · Cited by 10

Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on COVID-19 Infection in Kidney Transplant Recipients

Sutharattanapong, N., Thotsiri, S., Kantachuvesiri, S., & Wiwattanathum, P. (2022) · Vaccines · doi:10.3390/vaccines10040572 · Cited by 10

Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers

Oliveira-Silva, J., Reis, T., Lopes, C., Batista-Silva, R., Ribeiro, R. J. T., Marques, G., Pacheco, V., Rodrigues, T., Afonso, A., Pinheiro, V. C. A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.026 · Cited by 10

COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants

Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study

Meyers, E., Deschepper, E., Duysburgh, E., Rop, L. D., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · Viruses · doi:10.3390/v14112361 · Cited by 12

Control Strategies for the COVID-19 Infection Wave in India: A Mathematical Model Incorporating Vaccine Effectiveness

Sivadas, N., Panda, P., & Mahajan, A. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3210404 · Cited by 11

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study

Yan, V. K. C., Wan, E. Y. F., Ye, X., Mok, A. H. Y., Lai, F. T. T., Chui, C. S. L., Li, X., Wong, C. K. H., Li, P. H., Ma, T., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2209201 · Cited by 10

Untangling the changing impact of non-pharmaceutical interventions and vaccination on European Covid-19 trajectoriesPreprint

Ge, Y., Zhang, W., Wu, X., Ruktanonchai, C. W., Liu, H., Wang, J., Song, Y., Liu, M., Yan, W., Cleary, E., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1033571/v1 · Cited by 10

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

Link-Gelles, R., Levy, M. E., Natarajan, K., Reese, S. E., Naleway, A. L., Grannis, S. J., Klein, N. P., DeSilva, M. B., Ong, T. C., Gaglani, M., et al. (2022) · doi:10.1101/2022.10.04.22280459 · Cited by 10

A Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery

Song, S., Baek, J., & Seo, S. (2025) · Scientific Data · doi:10.1038/s41597-025-06456-w · Cited by 13

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review

Ocaña‐Guzmán, R., Osorio-Pérez, D., & Chávez‐Galán, L. (2023) · Pharmaceuticals · doi:10.3390/ph16081119 · Cited by 9

A Review on Nanosystem-Based Delivery of Tofacitinib for Enhanced Treatment of Autoimmune Diseases and Inflammation

Nguyen, T., & Duong, V. (2024) · BioNanoScience · doi:10.1007/s12668-024-01373-5 · Cited by 9

Incidence of Positive Severe Acute Respiratory Syndrome Coronavirus Polymerase Chain Reaction After Coronavirus Disease 2019 Vaccination With up to 8 Months of Follow-up: Real-life Data From the Capital Region of Denmark

Heftdal, L. D., Schultz, M., Lange, T., Knudsen, A. D., Fogh, K., Hasselbalch, R. B., Linander, C. B., Kallemose, T., Bundgaard, H., Grønbæk, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac012 · Cited by 9

Effectiveness of mRNA COVID-19 Vaccines in Adolescents Over 6 Months

Amodio, E., Genovese, D., Mazzeo, L., Martino, L., Restivo, V., Vella, G., Calamusa, G., & Vitale, F. M. (2022) · PEDIATRICS · doi:10.1542/peds.2022-057394 · Cited by 9

Emerging trends of research on mRNA vaccines: A co-citation analysis

Chen, J., Zhang, T., Lu, Y. Z., Yang, X., & Ouyang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2110409 · Cited by 10

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

Wang, F., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967051 · Cited by 10

Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review

Tian, W., Ren, X., Han, M., Zhang, Y., Gao, X., Chen, Z., & Zhang, W. (2022) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320221141802 · Cited by 9

Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study

Wan, J., Cazer, C. L., Clarkberg, M. E., Henderson, S. G., Lee, S. E., Meredith, G. R., Osman, M., Shmoys, D. B., & Frazier, P. I. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004153 · Cited by 9

Rapidly progressive IgA nephropathy with membranoproliferative glomerulonephritis-like lesions in an elderly man following the third dose of an mRNA COVID-19 vaccine: a case report

Morimoto, N., Mori, T., Shioji, S., Taguchi, T., Watanabe, H., Sakai, K., Mori, K., Yamamura, A., Hanioka, A., Akagi, Y., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03169-3 · Cited by 9

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data

Tene, L., Karasik, A., Chodick, G., Pereira, D. I. A., Schou, H., Waechter, S., Göhring, U., & Drakesmith, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285606 · Cited by 9

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial

Muangnoicharoen, S., Wiangcharoen, R., Nanthapisal, S., Kamolratanakul, S., Lawpoolsri, S., Jongkaewwattana, A., Thitithanyanont, A., Luvira, V., Chinwangso, P., Thanthamnu, N., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.043 · Cited by 9

Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population

Takemoto, Y., Tanimine, N., Yoshinaka, H., Tanaka, Y., Takafuta, T., Sugiyama, A., Tanaka, J., & Ohdan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1217206 · Cited by 9

Covid- 19 Vaccine-induced Myocarditis

Munjal, J., Flores, S. M., Yousuf, M. H., Gupta, V., Munjal, R. S., Anamika, F., Mendpara, V. A., Shah, P., & Jain, R. (2023) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1229 · Cited by 10

Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity

Silva‐Moraes, V., Souquette, A. H., Sautto, G. A., Paciello, I., Antonelli, G., Andreano, E., Rappuoli, R., Teixeira‐Carvalho, A., & Ross, T. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300041 · Cited by 10

Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV

Vergori, A., Cozzi‐Lepri, A., Matusali, G., Cicalini, S., Bordoni, V., Meschi, S., Mazzotta, V., Colavita, F., Fusto, M., Cimini, E., et al. (2023) · Vaccines · doi:10.3390/vaccines11121739 · Cited by 9

The impact of underreported infections on vaccine effectiveness estimates derived from retrospective cohort studies

Sacco, C., Manica, M., Marziano, V., Fabiani, M., Mateo‐Urdiales, A., Guzzetta, G., Merler, S., & Pezzotti, P. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae077 · Cited by 8

The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS)

Petráš, M., Lesná, I. K., Večeřová, L., Nyčová, E., Malinová, J., Klézl, P., Nezvedová, M., White, R. E., Máčalík, R., Dáňová, J., et al. (2021) · Vaccines · doi:10.3390/vaccines10010009 · Cited by 9

Depressive and Sexual Disorders during the First and Second Wave of the COVID-19 Pandemic among Young Polish Women

Szuster, E., Kostrzewska, P., Pawlikowska, A., Mandera, A., Biernikiewicz, M., Sobieszczańska, M. I., Roźek-Piechura, K., Jarząbek‐Bielecka, G., Rusiecka, A., & Kałka, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031887 · Cited by 9

mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic

Chen, P., Shi, X., He, W., Zhong, G., Tang, Y., Wang, H., & Zhang, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2040330 · Cited by 10

Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020–October 2021

Edelstein, M. L., Wiegler, K. B., Ben-Amram, H., Bar‐Zeev, N., Sussan, C., Asulin, H., Strauss, D., Bathish, Y., Zarka, S., & Jabal, K. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac212 · Cited by 10

Strategies and safety considerations of booster vaccination in COVID-19

Meng, H., Mao, J., & Ye, Q. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.7082 · Cited by 12

Effectiveness of COVID-19 Booster on the Risk of Hospitalization Among Medicare Beneficiaries

Mehta, H. B., Li, S., & Goodwin, J. S. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.06.029 · Cited by 9

Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method

Horváth, J. K., Ferenci, T., Ferenczi, A., Túri, G., Röst, G., & Oroszi, B. (2022) · Vaccines · doi:10.3390/vaccines10111824 · Cited by 11

COVID-19 stimulated travel behavior policy framework with evidence from travel change in southwestern Nigeria

Faiyetole, A. A. (2022) · Transactions on Transport Sciences · doi:10.5507/tots.2022.018 · Cited by 9

Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing

O’Shea, K. M., Schuler, C. F., IV, Chen, J., Troost, J. P., Wong, P. T., Chen, K., O’Shea, D. R., Peng, W., Gherasim, C., Manthei, D. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055429 · Cited by 8

Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States

Yang, F., Tran, T. N.-A., Howerton, E., Boni, M. F., & Servadio, J. L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03025-z · Cited by 10

The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence

Rosero‐Bixby, L. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35054 · Cited by 11

mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021

McLean, H. Q., McClure, D. L., King, J. P., Meece, J. K., Pattinson, D., Neumann, G., Kawaoka, Y., Rolfes, M. A. R., & Belongia, E. A. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12970 · Cited by 7

Understanding COVID-19 Vaccines Today: Are T-cells Key Players?

Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8

An epidemic model for SARS-CoV-2 with self-adaptive containment measures

Marchetti, S., Borin, A., Conteduca, F. P., Ilardi, G., Guzzetta, G., Poletti, P., Pezzotti, P., Bella, A., Stefanelli, P., Riccardo, F., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272009 · Cited by 8

Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection

Sajadi, M. M., Myers, A., Logue, J., Saadat, S., Shokatpour, N., Quinn, J., Newman, M., Deming, M. E., Tehrani, Z. R., Magder, L. S., et al. (2022) · mSphere · doi:10.1128/msphere.00279-22 · Cited by 10

Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi

Kaabi, N. A., Yang, Y., Hussein, S. E., Yang, T., Abdalla, J., Wang, H., Lou, Z., Bakkour, A. E., Arafat, A., Jiang, Z., et al. (2023) · Vaccines · doi:10.3390/vaccines11020299 · Cited by 8

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Dedroogh, S., Schmiedl, S., Thürmann, P., Graf, K., Appelbaum, S., Koß, R., Theis, C., Zia, Z., Tebbenjohanns, J., Thal, S. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34961-8 · Cited by 11

The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers

Jamalidoust, M., Eilami, O., Ashkan, Z., Ziyaeyan, M., Aliabadi, N., & Habibi, M. (2023) · Virology Journal · doi:10.1186/s12985-023-02156-2 · Cited by 7

Real-world effectiveness of COVID-19 vaccines among Colombian adults: A retrospective, population-based study of the ESPERANZA cohort

Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 8

New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups

Pourriyahi, H., Hajizadeh, N., Khosravi, M., Pourriahi, H., Soleimani, S., Hosseini, N., Mohammad, A. P., & Goodarzi, A. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1323 · Cited by 7

Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges

Corrao, G., Bertolaso, G., Pavesi, G., & Moratti, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031073 · Cited by 8

Estimating data-driven coronavirus disease 2019 mitigation strategies for safe university reopening

Yang, Q., Gruenbacher, D. M., & Scoglio, C. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0920 · Cited by 7

Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2

Saldaña, J., & Scoglio, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06477-0 · Cited by 8

Reliably Assessing Duration of Protection for Coronavirus Disease 2019 Vaccines

Lin, D.-Y., Zeng, D., Gu, Y., Krause, P. R., & Fleming, T. R. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac139 · Cited by 8

Optimizing Spatio-Temporal Allocation of the COVID-19 Vaccine Under Different Epidemiological Landscapes

Cao, W., Zhu, J., Wang, X., Tong, X., Tian, Y., Dai, H., & Ma, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.921855 · Cited by 8

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination

Bonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 8

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

Assavavongwaikit, P., Chantasrisawad, N., Himananto, O., Phasomsap, C., Klawaja, P., Cartledge, S., Nadsasarn, R., Jupimai, T., Kawichai, S., Anugulruengkitt, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10071098 · Cited by 8

Immune Response after mRNA COVID-19 Vaccination in Lung Transplant Recipients: A 6-Month Follow-Up

Tobudic, S., Benazzo, A., Koblischke, M., Schneider, L., Blüml, S., Winkler, F., Schmidt, H. M., Vorlen, S., Haslacher, H., Perkmann, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10071130 · Cited by 8

Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccination

Sararat, C., Wangkanai, J., Wilasang, C., Chantanasaro, T., & Modchang, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-21645-y · Cited by 7

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting

Rane, M. S., Robertson, M. M., Kulkarni, S., Frogel, D., Gainus, C., & Nash, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.039 · Cited by 7

COVID-19, Law & Regulation

Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · doi:10.1093/oso/9780192896742.001.0001 · Cited by 9

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

Gerhards, C., Thiaucourt, M., Hetjens, M., Haselmann, V., Neumaier, M., & Kittel, M. (2023) · Vaccines · doi:10.3390/vaccines11030701 · Cited by 10

Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study

Laydon, D. J., Cauchemez, S., Hinsley, W. R., Bhatt, S., & Ferguson, N. M. (2023) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00117-1 · Cited by 7

Evaluating vaccine allocation strategies using simulation-assisted causal modeling

Kekić, A., Dehning, J., Gresele, L., von Kügelgen, J., Priesemann, V., & Schölkopf, B. (2023) · Patterns · doi:10.1016/j.patter.2023.100739 · Cited by 7

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2

Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., Takeuchi, J. S., Horii, K., Ozeki, M., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08272-2 · Cited by 9

A bioengineered pseudovirus nanoparticle displaying SARS‐CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS‐CoV 2 challenge

Xia, M., López, K., Vago, F. S., Huang, P., Auguste, D. I., Jiang, W., Auguste, A. J., & Tan, M. (2023) · Biotechnology Journal · doi:10.1002/biot.202300130 · Cited by 8

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

Giuliano, A. R., Kuter, B. J., Pilon‐Thomas, S., Whiting, J., Mo, Q., Leav, B. A., Sirak, B. A., Cubitt, C. L., Dukes, C. W., Isaacs‐Soriano, K. A., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12453 · Cited by 8

A Stochastic Mobility-Driven spatially explicit SEIQRD COVID-19 model with VOCs, seasonality, and vaccines

Alleman, T. W., Rollier, M., Vergeynst, J., & Baetens, J. M. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.06.027 · Cited by 10

Comparative Analysis of Severe Clinical Outcomes in Hospitalized Patients with RSV, Influenza, and COVID-19 Across Early and Late COVID-19 Pandemic Phases (2021–2024)

Xing, Y., & Bahl, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144894 · Cited by 9

Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines

Kim, J. G., Xu, J., Lee, D., Song, J., Lee, S., Hong, M., Zhu, J., Zhu, A. T., Patwari, K., Shim, E.-H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c19036 · Cited by 8

COV-BOOST: evidence to support rapid booster deployment

Hall, V. J., & Hopkins, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02799-9 · Cited by 7

Improving vaccination coverage and offering vaccine to all school-age children allowed uninterrupted in-person schooling in King County, WA: Modeling analysis

Bracis, C., Moore, M., Swan, D. A., Matrajt, L., Anderson, L., Reeves, D. B., Burns, E., Schiffer, J. T., & Dimitrov, D. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022266 · Cited by 7

Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot

Παπαδοπούλου, Α., Stavridou, F., Giannaki, M., Paschoudi, K., Chatzopoulou, F. M., Gavriilaki, E., Georgolopoulos, G., Anagnostopoulos, Α., & Yannaki, E. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09863 · Cited by 7

A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database

Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11

SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort

Rizzi, M., Tonello, S., Brinno, C., Zecca, E., Matino, E., Cittone, M. G., Rizzi, E., Casciaro, G. F., D’Onghia, D., Colangelo, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1185278 · Cited by 7

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence

Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9

Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine

Chen, Z., Xie, F., Zhang, H., Dong, L., Zhang, S., Zhang, M., Li, J., Xie, J., Zhang, L., Yang, X., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1478627 · Cited by 10

From pandemic onset to present: five years of insights into ARDS caused by COVID-19

Ortiz‐Prado, E., Izquierdo‐Condoy, J. S., Vásconez-González, J., López‐Cortés, A., Salazar-Santoliva, C., Michay, A. R. V., Vélez-Páez, J. L., & Unigarro, L. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2507207 · Cited by 7

Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

Kilcoyne, A., Jordan, E., Zhou, A., Thomas, K., Pepper, A. N., Chappell, D. B., Amarapala, M., Hughes, A., & Thompson, M. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2030148 · Cited by 7

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

Zamagni, G., Armocida, B., Abbafati, C., Ronfani, L., & Monasta, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.825416 · Cited by 8

Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy

Fierro, A., Romano, S., & Antonella Liccardo, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265159 · Cited by 9

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort StudyPreprint

Tartof, S. Y., Slezak, J. M., Fischer, H. J., Hong, V. X., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909743 · Cited by 30

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative DesignPreprint

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111